Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Latest Advances in PDX Modelling for Oncology Drug Discovery

Published: Friday, September 13, 2013
Last Updated: Friday, September 13, 2013
Bookmark and Share
PRECOS' co-presentation with Crown Bioscience from Tumor Models Boston 2013 meeting available for download.

Preclinical Oncology Services Limited (PRECOS) has announced the availability of its co-presentation with Crown Bioscience delivered at the Tumor Models Boston 2013 meeting.

The presentation highlights the application of human surrogate trials to oncology drug discovery and how a comprehensive panel of PDX (Patient-Derived Xenograft) models of cancer can help better predict the effectiveness of drugs in clinical trials.

Historically the oncology drug development process is slow, expensive, inefficient and ultimately unsustainable. PRECOS and Crown Bioscience recognize the need to bring clinical decision-making earlier into the process.

Dr Aaron Cranston, Head of in vivo services, PRECOS Ltd comments, “Translating oncology drug discovery into improved patient outcome is the fundamental mission for both PRECOS and Crown Biosciences. By using human surrogate trials (HuTrials®) it is possible to identify biomarker signatures of patient responders and non-responders following treatment with targeted agents, reduce the attrition rate of new chemical entities (NCEs) in the clinic, accelerating drug development and improve chances of translational success.

By focusing on developing tumor models that are truly representative of patient outcomes, PRECOS and Crown Biosciences enable drug developers to overcome the challenges faced in preclinical oncology when testing new cancer drugs.

Problems in oncology drug development include a failure to consistently deliver highly effective drugs to patients, with many new drugs providing incremental benefit at non-incremental costs.

The ultimate goal in the oncology community is effective drug performance in the clinic and PDX models are superior in predicting efficacy and mimicking tumour activity in patients.

Also known as tumor graft models, PDXs are based on the transfer of primary tumors directly from the patient into an immunodeficient mouse.

PRECOS presented alongside its parent company Crown Bioscience on the latest developments in PDX modelling, highlighting the scale and skill of Crown Bioscience’s resources to maintain hundreds of in vivo PDX models in simultaneous passage ready for screening.

The presentation illustrates how PDX are being used today to discover biomarkers and run human surrogate trials using the world’s most comprehensive commercially available PDX collection.

The presentation is available to download via www.precos.co.uk/publications/ or email precos@scottpr.com to request a copy.

Dr Cranston continues, “PRECOS is committed to developing improved preclinical models and providing researchers with the very best oncology tools for superior predictions, which will ultimately lead to enhanced patient response. Molecular profiling and characterization underpins the models and the innovative approaches developed by PRECOS enable scientists to fast-track new agents into the clinic.”

Tumor Models 2013 was hosted in Boston from 23rd - 25th July. The meeting was attended by international researchers interested in optimizing models, exploring alternatives and predicting efficacy for enhanced clinical performance.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

PRECOS Appoints Dr Martin Page as Scientific Consultant
Appointment reinforces the ambition of PRECOS to contribute to the growing cancer therapy market.
Tuesday, February 21, 2012
PRECOS and Argenta Extend Collaboration to Offer World Class Integrated Oncology Drug Discovery Services
Five-year extension of the alliance allows both companies to offer unrivalled expertise in cancer research to their pharmaceutical clients.
Wednesday, March 23, 2011
PRECOS Secures Multi Year Global Service Agreement with Leading Pharmaceutical Company
PRECOS to provide clinical expertise to support Janssen’s oncology drug discovery, development and biomarker programmes.
Tuesday, November 23, 2010
Scientific News
Combining Chemotherapy With Immune-Blocking Drug Could Stop Cancer Growing Back
Giving patients a drug that blocks part of the immune system from going into overdrive might help prevent cancer coming back in some people.
Researchers Pioneer Use of Capsules to Save Materials
Wax capsule delivery systems can simplify a wide range of chemistry transformations.
Photoredox Catalyst Unlocks New Pathways for Nickel Chemistry
Using a light-activated catalyst, researchers have unlocked a new pathway in nickel chemistry to construct carbon-oxygen (C-O) bonds that would be highly valuable to pharmaceutical and agrochemical industries.
Scientists Determine How Antibiotic Gains Cancer-Killing Sulfur Atoms
In a discovery with implications for future drug design scientists have shown an unprecedented mechanism for how a natural antibiotic with antitumor properties incorporates sulfur into its molecular structure, an essential ingredient of its antitumor activity.
Familiar Drugs May Block Ebola Virus Infection
A well-known class of molecules, many of which are already in use therapeutically, may be able to block the Ebola virus’s entry into cells and halt the disease in its tracks, according to researchers at the University of Illinois at Chicago.
New Extra ‘Sticky’ Microgel Could Revolutionise Bladder Cancer Treatment
Researchers have designed a new super-efficient way of delivering an anti-cancer drug which could extend and improve the quality of life for bladder cancer patients - and perhaps save lives.
Common Class of ‘Channel Blocking’ Drugs May Find a Role in Cancer Therapy
Discoveries in fruit flies prompt unusual treatment of patient with metastatic disease.
Common Medications Could Delay Brain Injury Recovery
Drugs used to treat common complaints could delay the recovery of brain injury patients according to research by University of East Anglia (UEA) and University of Aberdeen scientists, published today in Brain Injury.
Scientists Make Strides in Therapy Preventing Addiction Relapse
Single Injection of Drug Candidate Prevents Meth Relapse in Animal Models.
New Clot-Busting Treatments Target Number One Killer
Australian researchers funded by the National Heart Foundation are a step closer to a safer and more effective way to treat heart attack and stroke via nanotechnology.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!